Regeneron Adopts Telesis Bio’s On-Demand DNA And mRNA Platform To Accelerate Biologics Discovery

Telesis Bio Inc., a pioneer in DNA and mRNA synthesis solutions, announced a new license agreement with Regeneron Pharmaceuticals to implement its Gibson SOLA™ platform within Regeneron’s R&D core facilities. The move will allow Regeneron to conduct automated, on-demand, high-throughput gene synthesis directly on-site, accelerating its biologics discovery workflows.

“Regeneron is one of the most forward-thinking biotechnology companies and is known for pushing the boundaries of scientific discovery and accelerating drug development. Adopting the Gibson SOLA platform is intended to enable full control of the nucleic acid supply chain and allows Regeneron to gain new insights that can aid in drug development. We are excited to support Regeneron’s efforts and to see how this platform could benefit their processes,” said Eric Esser, CEO of Telesis Bio.

Overnight, enzymatic DNA and mRNA synthesis on the Gibson SOLA platform takes only hours, replacing the previous weeks-long process of traditional gene synthesis. By producing this in their own facility, Regeneron reduces time for repetitions, maintains strong control over their IP and no longer depends on third-party providers.

Telesis Bio’s platform includes both reagents and software and can be integrated into most standard lab automation setups, offering scalable and flexible synthetic biology for a range of applications, including biologics, vaccines, and gene therapy. With exceptional dedication and purity, Gibson SOLA removes the need for time-consuming cloning and verification steps, enabling customers to streamline operations and boost productivity in drug development.